Schrödinger Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Schrödinger şirketinin toplam hissedar öz sermayesi $474.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $688.4M ve $214.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$377.29m
Eşitlik	US$473.98m
Toplam yükümlülükler	US$214.39m
Toplam varlıklar	US$688.37m

Son finansal sağlık güncellemeleri

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Aug 05

We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow

Nov 12

Recent updates

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Schrödinger: More Pharmaceutical Than Software

May 07

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

May 02

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Mar 01

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Mar 01

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Feb 28

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Feb 01

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Dec 18

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Sep 28

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Jul 01

Schrödinger: Q2 Earnings Supports Growth Narrative

Aug 26

Schrödinger appoints Dr. Geoffrey Porges as finance chief

Aug 18

Sizing Up Schrodinger

Jun 06

Schrödinger: Holding The Keys To Discovery

Mar 26

Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too

Mar 15

Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical

Jan 06

After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now

Nov 24

We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow

Nov 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SDGR 'nin kısa vadeli varlıkları ( $449.2M ) kısa vadeli yükümlülüklerini ( $99.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: SDGR şirketinin kısa vadeli varlıkları ( $449.2M ) uzun vadeli yükümlülüklerini ( $114.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SDGR borçsuzdur.

Borcun Azaltılması: SDGR son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SDGR şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: SDGR serbest nakit akışı her yıl % 40.9 2.3 yıl yetecek nakit akışına sahip olacaktır.

Schrödinger Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow

Recent updates

Schrödinger, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty

Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues

Consensus EPS estimates upgraded to US$2.42 loss

Schrodinger: More Drug Discovery Validation

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Schrödinger, Inc. Provides Earnings Guidance for the Third Quarter of 2024 and Fiscal Year Ending December 31, 2024

Schrödinger, Inc. to Report Q2, 2024 Results on Jul 31, 2024

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger: More Pharmaceutical Than Software

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Fiscal Year Ending December 31, 2024

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Schrödinger, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus revenue estimates fall by 18%

New minor risk - Share price stability

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Investor sentiment improves as stock rises 18%

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Price target decreased by 7.5% to US$43.67

Schrödinger, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Investor sentiment improves as stock rises 30%

Price target decreased by 14% to US$48.67

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$48.67

Price target decreased by 7.0% to US$54.44

Schrödinger, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 16%

Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Executive VP & CTO notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 23%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 8.4% to US$58.56

Chief Legal & People Officer notifies of intention to sell stock

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Price target increased by 7.3% to US$55.56

New major risk - Revenue and earnings growth

Independent Director exercised options and sold US$349k worth of stock

Consensus EPS estimates increase from loss to US$0.394 profit

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter and Full Year Ending December 31, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

Consensus EPS estimates upgraded to US$0.31 loss

Consensus EPS estimates fall by 21%

Price target decreased by 7.7% to US$51.38

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$606k worth of stock

Schrödinger, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO, President & Director exercised options and sold US$1.1m worth of stock

Forecast to breakeven in 2025

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921

Price target decreased to US$61.00

Price target decreased to US$61.00

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2021)

Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Schrödinger, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Schrödinger, Inc. Appoints Geoffrey Porges as CFO

Schrödinger: Q2 Earnings Supports Growth Narrative

Schrödinger, Inc. Announces CFO Changes

Schrödinger appoints Dr. Geoffrey Porges as finance chief

No longer forecast to breakeven

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Schrödinger, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Schrödinger, Inc. Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

Sizing Up Schrodinger